Rice Hall James & Associates LLC Buys 367,970 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Rice Hall James & Associates LLC raised its stake in scPharmaceuticals Inc. (NASDAQ:SCPH) by 59.2% in the 4th quarter, HoldingsChannel reports. The firm owned 989,635 shares of the company’s stock after acquiring an additional 367,970 shares during the quarter. Rice Hall James & Associates LLC’s holdings in scPharmaceuticals were worth $3,503,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SCPH. BNP Paribas Financial Markets increased its stake in scPharmaceuticals by 116.9% in the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after purchasing an additional 3,101 shares in the last quarter. Legato Capital Management LLC bought a new stake in shares of scPharmaceuticals during the fourth quarter worth about $37,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of scPharmaceuticals during the fourth quarter worth about $38,000. Virtu Financial LLC bought a new stake in shares of scPharmaceuticals during the third quarter worth about $46,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of scPharmaceuticals during the third quarter worth about $57,000. 89.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a research report on Thursday, November 14th. Craig Hallum decreased their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, November 14th.

scPharmaceuticals Stock Down 1.1 %

scPharmaceuticals stock opened at $3.64 on Wednesday. scPharmaceuticals Inc. has a fifty-two week low of $3.08 and a fifty-two week high of $6.54. The firm’s 50-day simple moving average is $3.39 and its 200 day simple moving average is $4.06. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.